Bayer, cross the hill
Update time:
2026-11-18 08:05
Reads:
The day Gong died, but the merit was not donated to Tang. Giant Bayer has finally emerged from its darkest moment.
In November 2023, with the clinical setback of the coagulation factor Ia inhibitor asundexian, Bayer's stock price experienced its largest single day decline in history, regressing to its performance in 2009. But now, things are very different.
Since that setback, after more than a year of dormancy, the stock price of this MNC has risen again by over 30%. As one of the main catalysts, asundxian has also successfully proven itself - in late October, it was the first to be approved for listing in the Chinese market; In early November, the product name Sunharbo received FDA approval.
Sebastian Guth, Global Chief Operating Officer of Bayer Pharmaceuticals, bluntly stated that the recurrence rate of stroke has not improved for a long time, and asundexian needs to become a product that truly changes practice.
Looking at Bayer's flagship products in terms of revenue, the patent cliff for the direct coagulation factor Xa inhibitor Xarelto is accelerating to collapse, while the VEGF inhibitor Eylea is also struggling in a downward channel facing biosimilar drugs and price pressure. These troubles forced Bayer to anticipate that its pharmaceutical business would not achieve growth until 2027.
This process obviously cannot be separated from new heavyweight products. And asundxian is precisely the world's first approved product in the FXIa inhibitor category, the first truly new mechanism for stroke secondary prevention in 20 years.
Analysts estimate that Asundexian's annual sales may reach as high as $4.5 billion. If it can repair the previous setbacks, this data can continue to rise to $5 billion or even higher.
However, in addition to competing with itself, this product also has to face the pursuit of competitors. The new story of Bayer crossing the hill may have just begun.
01. Victory in Flag Opening
One noteworthy point is that the first global outbreak of asundxian occurred in China.
On October 26th, NMPA approved the listing of asundexian (trade name Shuhuabo) through a priority review and approval process, for the purpose of reducing the risk of stroke in adult patients with non cardiogenic ischemic stroke or high-risk transient ischemic attack (TIA).
This new drug took about six months from submission of the marketing application to approval. This speed has practical considerations. It should be noted that the number of stroke patients in China is huge, with over four million new cases of ischemic stroke in 2023. The unmet need for secondary prevention constitutes a major support point for priority evaluation.
The FDA is following closely behind. On November 9th, asundxian was approved for use in combination with antiplatelet drugs to reduce the risk of stroke in adult patients who have recently experienced non cardiogenic ischemic stroke or high-risk TIA.
If unmet clinical needs are the driving force behind the rapid development and launch of asundexian, then the intrinsic quality of asundexian itself is the key to success.
The OCEANIC-STROKE study, which supports regulatory approval, randomly enrolled 12327 adult patients who had recently experienced non cardiogenic ischemic stroke (NIHSS ≤ 15) or high-risk TIA, and received either asundexian 50mg once daily or placebo in addition to standard antiplatelet therapy.
The primary endpoint - time of first ischemic stroke - occurred in 6.2% of patients in the asundexian group and 8.4% in the placebo group, with a relative risk reduction of 26%, a hazard ratio of 0.74, and an absolute risk reduction of 2.2 percentage points. The incidence of any stroke decreased from 8.8% to 6.6%, also driven by a reduction in ischemic events.
On the equally important safety side, the incidence of ISTH standard major bleeding was 1.9% in the asundexian group and 1.7% in the placebo group, with no statistically significant difference. In the context of secondary prevention of stroke, this is more difficult to achieve than efficacy figures.
Previous attempts to combine antiplatelet therapy with traditional anticoagulants have almost always encountered the same dilemma: just as ischemic events have decreased, intracranial and severe bleeding have increased, and the net benefits have been completely offset.
Andrew Russman, Director of the Comprehensive Stroke Center at Cleveland Clinic, commented that clinical practice has been limited to aspirin or clopidogrel, but the protection that antiplatelet therapy can provide has reached its ceiling. In addition, other drugs that act on the blood have always hung the risk of bleeding above the head. Therefore, the value of asundxian is self-evident.
It should also be pointed out that the cost is not zero, although it is small enough.
Gastrointestinal bleeding is more common in the asundexian group, with 2.7 events per 100 patient years compared to 2.1 events; The incidence of diarrhea is also slightly higher, 3.4% compared to 2.8%. Elevated liver enzymes are listed as a safety signal of concern in prescription information, and patients with moderate to severe liver injury are excluded from the recommended medication range.
Anyway, asundxian made history by becoming the first FXIa inhibitor.
Bayer has priced the 30 day supply of asundexian at $748.50, equivalent to an annual treatment cost of approximately $9100. Wall Street investors' expected upper limit for peak annual sales is around $4.5 billion, which is a real bombshell product.
02. Resurrected from the dead
Pioneers who make a difference always have to endure setbacks, to the point of almost becoming martyrs.
FXIa inhibitors are one of the most promising new directions in the field of anticoagulation. The logical chain is concise and enticing: FXIa plays a role in the amplification stage of endogenous coagulation pathways and is a key enzyme for pathological thrombus amplification; But its contribution to daily hemostasis is minimal.
The population with congenital FXI deficiency - approximately 12 out of every 100 people with less than half of normal activity - has a lower risk of ischemic cardiovascular events but rarely experiences spontaneous bleeding. The figure given by an epidemiological study involving 10000 people is that for individuals with FXI activity between 30% and 50%, the adjusted cardiovascular risk ratio is 0.52.
Therefore, inhibiting FXIa theoretically can separate "bad thrombosis" from "normal hemostasis".
Bayer has been betting on this hypothesis for a long time and has invested heavily in it. The OCEANIC project is being rolled out on multiple indications simultaneously, with atrial fibrillation stroke prevention being the most commercially promising one.
OCEANIC-AF enrolled 18000 atrial fibrillation patients and compared asundexian 50mg once daily with apixaban 5mg twice daily in a head to head manner.
However, in November 2023, the interim analysis by the Independent Data Monitoring Committee provided an inconclusive result: asudesian was inferior to apixaban in the primary efficacy endpoint of stroke or systemic embolism, with a risk ratio of 3.79 and a ratio of 1.3% to 0.4%; Ischemic stroke was also higher in the asundexian group, at 1.1% compared to 0.3%.
On the evening of the announcement, Bayer's European stock opened down nearly 20%, hitting a 12 year low.
There are doubts in the market - if FXIa inhibition cannot beat existing Xa factor inhibitors in atrial fibrillation, can this category be established in any major indication?
However, the paper published in JACC suggests that the research results of OCEANIC-AF may not represent class effects, but rather reflect insufficient dosage and other design considerations. Therefore, there is still a clinical equilibrium (uncertainty) regarding the efficacy of other coagulation factor XI/XIa inhibitors; Thousands of research centers are still conducting trials for coagulation factor XI/XIa, which demonstrates this point.
In other words, Bayer's study is more like a failure in indication selection.
Thrombosis in atrial fibrillation occurs in an atrial environment with low shear stress, low flow velocity, and low pressure, which is closer to venous thrombosis in terms of pathophysiology; The trigger environment of atherosclerotic stroke is plaque rupture and platelet activation under high shear stress. FXIa inhibition may have a different benefit risk curve on the arterial side compared to the venous side.
The validity of this hypothesis depends on the trials of secondary stroke prevention. OCEANIC-STROKE is the answer.
In February 2026, at the main venue of the International Stroke Conference, the positive results of OCEANIC-STROKE for asundxian were announced. The relative risk was reduced by 26%, and the bleeding curve almost matched the placebo.
Another molecule of the same category, milvexian, was discontinued prematurely due to ineffectiveness in the phase III trial LIBREXIA-ACS for acute coronary syndrome, with a risk ratio of 1.05. The ischemic events did not decrease after the addition of milvexian.
ACS and stroke secondary prevention are highly similar in design - both adding a layer on top of standard antiplatelet therapy and both compared to placebo - but the results are ineffective and significant. The difference lies in the background treatment intensity of the enrolled population: In the ACS trial, over 95% of patients were already using dual antiplatelet therapy at baseline, and nearly 60% were using potent P2Y12 inhibitors, with antiplatelet therapy reaching its peak; The background treatment intensity of stroke trials leaves room for the incremental value of FXIa inhibition to be revealed.
FXIa inhibitors hit the wall on ACS and chiseled open the door on stroke.
03. Behind the Hill
Similar to Asundexian's experience, Milvexian from BMS and Johnson&Johnson failed, but was also not abandoned.
In terms of secondary prevention of stroke, Milvexian has a phase III trial called LIBREXIA-STROKE, which includes 15000 participants and is still under follow-up. Data is expected to be available between the end of 2026 and the beginning of 2027.
Although Christine Roth, Global Product Strategy and Commercialization Head of Bayer Pharmaceuticals, emphasized that asundxian "sets a high threshold" in terms of efficacy and bleeding control, milvexian is indeed a variable that needs to be closely monitored, determining whether Bayer continues to dominate the market or must share it with peers.
At the same time, Bayer also has more work to complete.
Firstly, the window period for stroke prevention is approximately one year, which is quite long - because the prescription decisions for secondary stroke prevention are highly dependent on guidelines and clinical pathways, and once they enter the guidelines, the first mover advantage is easily amplified; Short is short - after all, payers never wait for competitors to examine the cost of expensive new drugs, with annual treatment costs exceeding $9000, while generic drugs of aspirin and clopidogrel are priced in cents.
Bayer needs to prove to the insurance company that a relative risk reduction of 26% and an absolute risk reduction of 2.2 percentage points are worth the price in a population with a five-year recurrence rate of about 20%.
Secondly, expanding indications is also an unfinished business. Although atrial fibrillation has experienced the failure of OCEANIC-AF, the OCEANIC-AFINA trial is still planned, targeting a subgroup of atrial fibrillation patients who are considered unsuitable for standard anticoagulant therapy.
If this subgroup can be established, the commercial ceiling of asundxian will extend outward from the patient population for secondary stroke prevention.
It is particularly important for Bayer today to do everything possible to expand its successful territory.
Between 2023 and 2025, the pharmaceutical department of this giant will be struggling: old products are accelerating their decline on the patent cliff, while new products such as Nubeqa and Kerendia are increasing in volume - Nubeqa grew 56% year-on-year and Kerendia grew 73% in the third quarter of 2026- but their combined size is not enough to fill the void left by Xarelto alone. The addition of asundxian undoubtedly provides more assistance for its restructuring.
In the third quarter of 2026, Bayer Pharmaceuticals' sales increased by 8% year-on-year, approaching 4.7 billion euros.
The management of the company has referred to the first batch of Asundxian in China as a "major milestone", but the determination of whether this drug can become a growth engine also depends on the volume curve of the US market, as well as regulatory decisions still under review in Europe and Japan.
As the "fire brigade leader", Bayer's new CEO Bill Anderson has launched a sweeping reform, pushing for the cutting of about 14000 positions and a nearly 70% reduction in management levels.
2026 is defined by Bayer as the "last roughly flat year" for the pharmaceutical sector, after which growth needs to be taken over by new products. Anderson has rejected calls on multiple occasions to separate pharmaceuticals from crop science, citing the need for "focus" rather than "structural adventure".
It can be said that the approval of asundxian is the first hard evidence presented by this focused strategy. But where Bayer can go next depends on how well the story is told.
The two approvals of Asundexian are the milestone for FXIa inhibitors to move from hypothesis to clinical practice. Whether the new mechanism can support a wider range of cardiovascular indications, whether the technology can be scaled up, and whether the Chinese and global markets can synchronize with the increase in volume are related to the next stage of this category.
The 2026 China Medical City Health Industry Forum, hosted by the Taizhou Municipal People's Government, will be held in Taizhou from November 19th to 21st. The forum is themed "Empowering Big Health with Biomanufacturing, Leading a New Future with Innovation Integration" and adopts a "1+6+1" architecture. Among them, the special topic of "Frontier Technologies and Future Industries" will focus on the research and industrialization of cutting-edge directions such as oxygen carrier artificial blood and emergency drugs for myocardial infarction, jointly exploring the engineering proposition from clinical evidence to scale accessibility.
Reference materials:
Bayer brings factor XIa to US stroke prevention with FDA nod for 1st-in-class asundexian
New Type of Blood Thinner Approved to Prevent Repeat Strokes
Bayer, bitter waiting to turn the tide
Bayer's darkest moment
The world's first batch! Bayer's new FXIa inhibitor Ashuximab tablets have been approved for market, ushering in a new era of stroke treatment
Previous page
Related News